Tislelizumab & Tremelimumab Among Latest Filings In EU

 
• By Neena Brizmohun

The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
EU marketing applications for new drugs are under review • Source: Alamy

More from Europe

More from Geography